Elicio Therapeutics, Inc. — Form 8-K
Filed August 13, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 52/100
What the filing says
Elicio's Phase 2 AMPLIFY-7P trial of ELI-002 7P in adjuvant mKRAS pancreatic cancer did not meet primary endpoint, but the company observed multiple complete responses in metastatic disease with checkpoint inhibition. The company raised $15.0M gross ($16.6M net via ATM in Q2) to fund a Phase 1 combination study with RAS inhibitor ± anti-PD-1, anticipated Q4 2026 initiation. Cash position of $23.5M as of June 30, 2026 supports operations into Q1 2027.
Why this rating
Phase 2 failure is material setback, but encouraging metastatic signals and near-term funding provide path forward. Magnitude comparable to company size but trajectory unclear pending Phase 1.
See more from August 13, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.